CTMX

CytomX Therapeutics, Inc.
CAPPED RATING

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.

CytomX Therapeutics, Inc. (CTMX) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Growth (D). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.8 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
D
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.8
EV / EBITDA -0.9
Rev Growth YoY -71.7%
Gross Margin N/M
Price Return 3M -43.3%
Price Return 12M -45.3%
Catalyst Signal 0.00
Market Cap $431.6M
TTM Revenue $14.0M
Price / Sales 30.8
ROE -43.6%

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.8) D (1.2) C (2.2) D (1.5) C+ (2.6) C- (2.0)
2026-11-04 B- (2.9) D- (1.0) C (2.2) D+ (1.6) C+ (2.7) C- (2.1)
2026-10-28 B- (2.9) D- (1.0) C- (2.1) D+ (1.7) C+ (2.7) C- (2.1)
2026-10-21 C+ (2.8) D- (1.0) C (2.2) D+ (1.6) C+ (2.6) C- (2.1)
2026-10-14 B- (2.9) D- (1.0) C (2.2) D+ (1.7) C+ (2.6) C- (2.1)
Page 1 of 5